Palbociclib/palbociclib for triple negative breast cancer?

Triple-negative breast cancer refers to breast cancer that is negative for estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2). This type of breast cancer is often difficult to treat because it lacks therapeutic targets for these three receptors. However, palbociclib, a CDK4/6 inhibitor, provides new possibilities for the treatment of triple-negative breast cancer.

Palbociclib can selectively inhibit cyclin-dependent kinases4 and 6 (CDK4/6), restore cell cycle control, and thus block the proliferation of tumor cells. This provides an effective means to control the growth and spread of triple-negative breast cancer.

In clinical trials, palbociclib combined with other treatments (such as letrozole) has shown significant efficacy in triple-negative breast cancer. For example, in one study, palbociclib combined with letrozole was used to treat patients with hormone receptor (HR)-positive, HER2-negative breast cancer. The median progression-free survival was as long as 24.8 months. Compared with letrozole alone, the patient's survival was significantly longer.

Although patients with triple-negative breast cancer do not expressER and PR, palbociclib can still have a therapeutic effect on it by inhibiting the mechanism of CDK4/6. This provides new treatment options for patients with triple-negative breast cancer.

Palbociclib is mainly used to treat HR-positive, HER2-negative locally advanced or metastatic breast cancer. However, in actual clinical applications, doctors will also consider using palbociclib for treatment based on the specific conditions of triple-negative breast cancer patients.

Before taking the drug, patients should be tested in a qualified pathology laboratory to confirmHR positive and HER2 negative before use. At the same time, the starting dose of palbociclib is usually 125 mg/day, with a medication cycle of 4 weeks, including 1 week of discontinuation after 3 weeks of medication.

The use of palbociclib may cause some side effects, such as neutropenia, infection, leukopenia, fatigue, etc. Therefore, it is necessary to closely monitor the patient's physical condition during use and adjust the treatment plan in a timely manner.

Overall, palbociclib provides a new treatment option for patients with triple-negative breast cancer. Although it is not a drug specifically targeted at triple-negative breast cancer, its unique mechanism of action allows it to have a therapeutic effect on this type of breast cancer in some cases. However, the specific medication regimen and effect need to be determined based on the patient's specific situation and the doctor's recommendations. If the patient has more questions about palbociclib, please consult a professional doctor.